Page 1,350«..1020..1,3491,3501,3511,352..1,3601,370..»

Section of Molecular Medicine | Wake Forest School of Medicine

Posted: November 9, 2018 at 10:41 am

The Section of Molecular Medicine focuses on performing cutting-edge research in cellular and molecular mechanisms of human disease and supports graduate and postgraduate level educational programs within the Department of Internal Medicine.

A major goal of the section is to serve as a nidus for translational research by providing an environment where clinical and basic science faculty interact to make new discoveries and to educate future scientists.

The section consists of 24 primary faculty members and two emeritus faculty members who use cellular and molecular approaches to gain a better understanding of the basic mechanisms underlying acute and chronic human conditions, including sepsis, arthritis, atherosclerosis, diabetes, obesity, fatty liver, and cancer.

Molecular Medicine faculty collaborate on forward (disease/phenotype -> molecule) and reverse (molecule mutation/deletion -> disease phenotype) translational research to bidirectionally link new molecule discovery to disease pathogenesis using state-of-the-art omics (transcription, epigenetics, proteomics, metabolomics, lipidomics) and gene editing/deletion/overexpression technologies.

The Molecular Medicine Section is the academic home for the Molecular Medicine and Translational Science (MMTS) graduate program, one of the largest biomedical sciences graduate programs at Wake Forest University. MMTS offers PhD and MS training for BS, MD and DVM students. The section also provides laboratory research training and education in translational research for medical students, residents and postdoctoral fellows, including subspecialty fellows in the Department of Internal Medicine. A seminar series and journal club are held weekly as part of the training program in MMTS.

We invite you to explore our department and contact us with any questions you may have.

See the original post:
Section of Molecular Medicine | Wake Forest School of Medicine

Posted in Molecular Medicine | Comments Off on Section of Molecular Medicine | Wake Forest School of Medicine

Hormone Replacement Therapy Doctors in New York – HRT …

Posted: November 8, 2018 at 1:43 am

The Big Apple can eat you alive if youre not at the top of your game. New York residents need not worry: HealthGains and its premium hormone therapy plans can help you get ahead personally and professionally. Over the past decade, HealthGains has treated countless patients for low testosterone and other hormone imbalances. Now its your turn to experience the benefits of hormone replacement therapy. Our prime location in NYC makes it easy to stop by and learn more about our services firsthand. Take a look at our sexual wellness performance packages for men and women.Will Bio-Identical Hormones Work for Me?

Only an exhaustive workup will reveal if youre a good candidate for hormone replacement therapy. Our blood work is comprised of 15 different tests designed to provide an overview of your health and pinpoint any imbalances in your hormone levels. Once we see that hormones might be causing your symptoms, well schedule you some time with an HealthGains doctor to review your symptoms and get you started on HRT. Its that simple. Please keep in mind that not everyone is a good candidate for hormone replacement. If our lab tests reveal that your hormones fall within an ideal range, we may not prescribe HRT. Contact us at (866) 540-3555 to speak with one of our hormone specialists.

The signs of low hormone levels can often be confused with symptoms from other conditions. If youve been feeling less energetic, less focused or less interested in sex, your hormones could be to blame. The only way to find out is through comprehensive. Together, we can get your health back to where it once was. Let us help you. HealthGains NYC Phone: (212) 897-3742 65 Broadway, Suite 1101 New York, NY 10006

*Click location to see full list of addresses

Continue reading here:
Hormone Replacement Therapy Doctors in New York - HRT ...

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Doctors in New York – HRT …

Leadership U.S. Transhumanist Party Official Website

Posted: November 8, 2018 at 1:42 am

Officers

Gennady Stolyarov II ChairmanBobby Ridge SecretaryB.J. Murphy Director of Social MediaFranco Cortese Director of ScholarshipDinorah Delfin Director of Admissions and Public RelationsArin Vahanian Director of MarketingSean Singh Director of Applied InnovationKenneth Alum Director of PublicationEmanuel Iral Director of Visual Art

Foreign Ambassadors

Keoma Ferreira Antonio BrazilAngel Marchev, Sr. BulgariaAria Cheng CanadaAiken Nen Iavarrone ChileAbdul-Rahman Essam Saleh EgyptChris Monteiro EnglandPam Keefe Hong KongPalak Madan IndiaDenisa Rensen JapanOjochogwu Abdul NigeriaBobby Pembleton ScotlandJos Luis Cordeiro Spain

Representatives of the Worldwide Transhumanist Movement

Alexandr Putyatinskiy Representative of the Transhumanist Movement in Kazakhstan

Officers

Gennady Stolyarov II (G. Stolyarov II) became the second Chairman in the history of the Transhumanist Party in November 2016. Mr. Stolyarovis an actuary, independent philosophical essayist, science-fiction novelist, poet, amateur mathematician, composer, and Editor-in-Chief of The Rational Argumentator, a magazine championing the principles of reason, rights, and progress. Mr. Stolyarov regularly produces YouTube Videos discussing life extension, politics, philosophy, and related subjects.

In December 2013, Mr. Stolyarov published Death is Wrong, an ambitious childrens book on life extension. Death is Wrongcan be found on Amazon in paperback and Kindle formats, and can also be freely downloaded in PDF format in the English, Russian, French,Spanish, and Portuguese languages.

Mr. Stolyarov is the Chief Executive and one of the founding members of the Nevada Transhumanist Party, established in August 2015.

Mr. Stolyarov has contributed articles to the Institute for Ethics and Emerging Technologies (IEET), The Wave Chronicle, Le Qubcois Libre, Brighter Brains Institute, Immortal Life, Enter Stage Right, Rebirth of Reason, The Liberal Institute, and the Ludwig von Mises Institute.

Mr. Stolyarov holds the professional insurance designations of Fellowof the Society of Actuaries (FSA), Associate of the Casualty Actuarial Society (ACAS), Member of the American Academy of Actuaries (MAAA), Chartered Property Casualty Underwriter (CPCU), Associate in Reinsurance (ARe), Associate in Regulation and Compliance (ARC), Associate in Personal Insurance (API), Associate in Insurance Services (AIS), Accredited Insurance Examiner (AIE), and Associate in Insurance Accounting and Finance (AIAF).He is the author of numerous actuarial study guides, including, most recently, the 473-page Practice Problems in Advanced Topics in General Insurance, published by ACTEX Learning.

Mr. Stolyarov has written a science-fiction novel, Eden against the Colossus, a philosophical treatise, A Rational Cosmology, a play, Implied Consent, and a free self-help treatise, The Best Self-Help is Free.

In an effort to assist the spread of rational ideas, Mr. Stolyarov published his articles on Associated Content (subsequently the Yahoo! Contributor Network and Yahoo! Voices) from 2007 until Yahoo! closed this venue in 2014. Mr. Stolyarov held the highest Clout Level (10) possible on the Yahoo! Contributor Network and was one of its Page View Millionaires, with over 3,191,000 views. Mr. Stolyarovs selected writings from that era have been preserved on this page.

Mr. Stolyarov can be contacted here.

Bobby Ridgehas a Bachelors Degree in Biomedical Science from California State University of Sacramento (CSUS) and is striving to achieve his PhD in Neuroscience. He only recently found transhumanism and became a Transhumanist. He conducted research for CSUSs Psychology Department and his own personal research on the epistemology and Scientiometrics of the Scientific Method. He also co-owns Togos in Citrus Heights, CA. Mr. Ridge considers transhumanism to describe the future of humanity taking its next steps in evolution, which are both puissant and daunting. With the exponential increase in information technology, Mr. Ridge considers it important for us to become a science-based species to prevent a dystopian-type future from occurring.

Mr. Ridge can be contacted here.

B.J. Murphy is a writer, author, futurist, and activist. He has done work as a Technology Adviser for short films and television and is an Ambassador for both the A.I. company Persona and robotics company BodAi. Hes an Editor and Social Media Manager for Serious Wonder, Affiliate Scholar for the Institute for Ethics and Emerging Technologies, and is a co-author of both The Future of Business: Critical Insights Into a Rapidly Changing World From 60 Future Thinkers and 50:50 Scenarios for the Next 50 Years.

Mr. Murphy can be contacted here.

Franco Cortese is the Deputy Director of the Biogerontology Research Foundation and a member of its Board of Trustees. He believes that the most effective and economical approach to the treatment of age-related diseases which represent, from both a quantitative and qualitative standpoint, some of the most significant diseases afflicting humanity today is through the extension of healthspan via biomedical interventions focusing on the prevention, negation, and/or slowing of accumulated age-related phenotypic deviation. In addition to his administrative and research activities, Cortese has also written extensively on the ethical, socioeconomic, political, logistical, and philosophical implications of biomedical gerontology.

He is also active as a research scholar in the field of the philosophy of technology, focusing on the ethical, sociological, philosophical, and political issues surrounding emerging technologies in general and human enhancement technology in particular through his work as an Affiliate Scholar of the Institute for Ethics & Emerging Technologies (IEET), a technoprogressive policy institute focusing on the social implications of emerging technologies. His most recent research in this area has involved articulating a novel variant of technological determinism titled technic self-determination (Cortese, F. A. B. (2014). Technic Self-Determination. In Stephen John Thompson (Ed.), Global Issues and Ethical Considerations in Human Enhancement Technologies (pp. 203-224). Hershey, PA: IGI Global; Cortese, F. A. B. (2016). The Technoethical Ethos of Technic Self-Determination. International Journal of Technoethics (IJT), 7(2), 1-27), which posits a reciprocally causative relationship between technology and society, construing technology to be a crucial and reciprocally causative ontological fundament of human nature.

Among other broader research topics relating to the ethical, philosophical, and sociopolitical implications of emerging technologies in general, his current research involves defending the development and proliferation of human enhancement technologies (HET) as a viable means of increasing the capacity for self-determination, autonomy, and sovereignty at the level of both society and the individual and of reducing unnecessary suffering in the world at large by increasing the capacity for individuals to determine the controlling circumstances of their selves and lives. Contrary to many critics of HET, Cortese argues that the use of HET exemplifies and indeed even intensifies our most human capacity and faculty namely, the desire for increased self-determination, which he refers to as the will toward self-determination. Furthermore, he argues that the use of HET bears fundamental ontological continuity with the human condition in general and the historically ubiquitous will toward self-determination in particular, and that, as such, the development and proliferation of HET need not be a dehumanizing force, but rather could very well serve to increase the very capacity that characterizes us as human more accurately than anything else, provided that it is developed and proliferated democratically and ethically.

Corteses other current positions and affiliations include Associate at Deep Knowledge Life Sciences, Research Scientist at ELPIs Foundation for Indefinite Lifespans, Scientific Advisor for Lifeboat Foundation (Life Extension Advisory Board and Futurists Advisory Board), Honorary Fellow of Brighter Brains Institute, Chief Operating Officer of the Center for Interdisciplinary Philosophic Studies, International Coordinator of Cryonics Switzerland, Ambassador for the Seasteading Institute, Assistant Editor at Ria University Press, Member of the International Longevity Alliance, Chair and Co-Founder of the Canadian Longevity Alliance, and Reviewer for the Global Futures Intelligence System at The Millennium Project.

Mr. Cortese can be contacted here.

Dinorah Delfin is a Multi-Media New York Artist and Futurist with a clear mission: to advocate for the ethical use of emerging technologies to help steer humanity into a thriving metahumanity. She is the owner of ArtDimensional Studios, Inc., in New York and has a degree in Business Management. Ms. Delfins artworks and activism are aimed to raise critical questions about emerging techno-social structures as they become more embedded in our lives, and our evolving definition of humanity, individual sovereignty, and general happiness and sense of purpose. Ms. Delfins artworks can be seen on her Instagram page.

Ms. Delfin has been designing a grass-roots campaign to advocate for the ethical use of emerging technologies including a manifesto and a series of propaganda-like posters that raise questions about emerging technologies and how they affect our everyday life. With the assistance of like-minded artists, she is planning to carry on a guerrilla-type campaign both online and in public spaces such schools. She has been involved in organizing educational events as well as fundraisers for charitable relief efforts.

Ms. Delfin can be contacted here.

Arin Vahanian is a project manager, author, entrepreneur, musician, blogger, startup advisor, and aspiring electrical engineer. Having worked for three Fortune 100 companies and several technology startups, Mr. Vahanian helps organizations build high-performance teams and create and launch products/services that delight the customer.

Being deeply devoted to the promise of Transhumanism and the concept of continuous improvement, Mr. Vahanian is the author of Kaizen for Men, a book that combines self-help with Lean Manufacturing and Toyota Production System principles, helping men boost their health, career, and relationships.

Mr. Vahanian became interested in the Transhumanist movement after coming across various life-changing technologies and breakthroughs in the medical field. His personal vision is to live and love deeply, being dedicated to building and spreading technologies that allow human beings to live more fulfilling, joyful, and enhanced lives. Specifically, he has a special interest in curing mental health disorders such as depression and social anxiety disorder, as well as reversing aging and curing dementia and other neurological disorders.

Mr. Vahanian holds a Bachelors degree in Journalism (Public Relations) and a Master of Business Administration (Management) degree from California State University, Northridge. Additionally, he holds several professional certifications in the information technology (IT) industry, and is an Enrolled Agent.

A seasoned traveler and expatriate, Mr. Vahanian has lived and worked on three continents, and speaks six languages. Mr. Vahanian is an ENTJ personality type according to the Myers-Briggs Type Indicator.

Mr. Vahanian can be contacted here.

Sean Singh is a dedicated supporter of human rights and environmental justice, an expert in strategy, quality control, and lateral thinking, with a life-long passion for open-source technologies. He is the founder of SolarFi Networks, an Internet Service Provider (ISP) that designs and deploys metro-scale wireless networks that are disaster-resilient. He has owned and operated several commercial data centers, having worked in every role from tech support to network administrator to infrastructure design and implementation beforehand. Mr. Singhs passion also extends to education. He takes an open-source view that education should be free to anyone interested, and to that end he works with the Open Source Temple, one the worlds first Transhumanist churches. Mr. Singh worked closely with Todd Freeman to develop the ranking system for consciousness that appears at the beginning of the Transhumanist Bill of Rights Version 2.0, and which reflects his familiarity with bridging the gap between neuroscience and digital intelligence.

Mr. Singh can be contacted here.

Kenneth Alum has an Advanced Diploma in Business Management, with technical skills in Computer Hardware and Software maintenance (A+). His work experience spans 15 years, 12 years being in lower to senior-level management. Mr. Alum has worked in the industries of Graphic Design, Print Advertising, Insurance, and Finance, and has spent 10 years in the micro-finance industry. He has accrued skills in policy and procedure writing and implementation, credit appraisal, loan marketing, budgeting, financial forecasting, credit control, staff training, graphic design, report writing, business planning, customer service, and branding.

Mr. Alum has taken keen interest in science and technology recently. He now considers himself a Transhumanist, Futurist and a Space Ager an advocate for space and for new worlds exploration, habitation, and colonization. Mr. Alum just began private studies in biotechnology and hopes to do the same with nanotechnology and various space technologies. He will eventually proceed to acquire formal education on these disciplines. Mr. Alum has created the Facebook group Transhumanism Africa and started a business in Kenya named Transhumanism Technologies. The purpose of the business is to import to Africa and trade in new technology products in the future.

Mr. Alum can be contacted here.

Emanuel Iral is a design freelancer who has provided clients with work ranging from typical advertisements, flyers, and logos, to filming and editing videos. Mr. Iral has interned as a studio assistant to a prominent artist in New York, Laetitia Soulier. He has participated in one art show, Young Artist Initiative, in Miami, where he exhibited his series of 70+ pencil drawings of carved bodies. Mr. Irals artwork ranges from traditional paint and pencil work to 3D digital work. Currently he is working on his VFX and animation skills, as he is producing short films for his music.

Mr. Irals work can be found on Behance.net, Instagram, and Patreon. Heencompasses his art under the term Prismatis Latin for prism. A prismrefracts white light into the three primary colors: yellow, magenta, and cyan. Prismatis is all about the aesthetic of human expression, which can be separated into the art, audience, and artist.

Mr. Iral can be contacted here.

Foreign Ambassadors

Keoma Ferreira Antonio is a philosopher, musician, and lover of science fiction and Japanese art production. Graduated in Philosophy from UFRN (Federal University of Rio Grande do Norte, Brazil), he was a laureate of his class. He currently holds a masters degree in philosophy from the same university, and his research area is Transhumanism.

He researches and writes about the Promethean-Faustian Oscillations of Transhumanism, which come from the demiurgic character of modern sciences (which will be published as an introductory book on transhumanism). He is also a member of the research group on Immortality, an activist of the Transhumanist cause (being an active voice within the movement, which is still small in Brazil) and works with the dissemination of philosophical thought through anime (Japanese animation).

Keoma can be contacted here.

Prof. Angel Marchev, Ph.D. has graduated as automation control engineer at the Technical University of Sofia. Later he worked closely with A. Ivahnenko, one of the originators of the concept of Self-organization.

Prof. Marchev is one of the pioneers of implementing cybernetics and system theory in the fields of business management in Bulgaria. Over the last 40 years he has published more than two hundred papers on various topics in the field. He considers as his life-time achievement the implementation of Multi-stage selection procedures for wide range of business challenges such as system identification, forecasting, modeling economic and business systems among others.

Angel Marchev, Sr. is one of the pioneers of implementing computer business games and active methods in education for adults in Bulgaria. Over the last 40 years he has educated more than thirty thousand students and managers using over hundred and twenty CMG and other active methods in his courses. He teaches courses such as Simulation and gaming in management, Business games, Computer simulation and forecasting, Financial modeling in management and Fundamentals of Management I: Cybernetics and systems theory at the University for National and World Economy and Burgas Free University among several others business schools and collages in Bulgaria and at University of Hasselt, University of Slough, and London Guildhall University among others abroad.

By using games he has trained a spectrum of Bulgarian business leaders starting with his assignment at the Center for training management resources throughout the 1970s. In the last 20 years he has started his own consultancy business providing training for various private and public organizations.

Prof. Marchev has been among the first members of ISAGA since it was founded and was member of the steering committee of ISAGA almost until 1990. He was also a member of EESAGA. Now he is establishing BASAGA in Bulgaria.

Professor Marchev can be contacted here.

Aria Chengis a Wholistic Transhumanist Artist, Designer, Community Builder, Advocate, and Entrepreneur. As an unprotected visible intersectional minority with invisible disabilities, Aria has spent 6 years engaged in building inclusive queer and feminist communities and spaces, and an additional 10 years serving her local community in many capacities.

Since her departure from the queer-feminist activist sphere in 2013, Aria remains a passionate Transhumanist, with a distinct progressive vision for Canadas future which includes: a focus on Innovation and Research; extending Universal Care to encompass Basic Income, Advanced Education, and extended Health & Dental coverage for longevity; an actionable plan for Native Reparations; Voting Reform; and making use of Blockchain technology and Artificial Intelligence for true democratic participation as well as the distribution of both private and public services; among others.

Aria is currently working on finishing her Associate Degree of Arts in Social Sciences, as well as her Diploma of Fine Arts. She also serves as Lead Designer for the non-profit humanitarian AI organization, Robots Without Borders, and is Founder of The Transhumanist Party of Canada.

In her personal life, Aria is giant fan of Star Trek, loves her two cats, and identifies her gender to be Transhumanist.

Aiken Nen Iavarrone graduated in Electronics in high school and participates in the maker movement in Chile. He is a student of automation and industrial control and is interested in the Fourth Industrial Revolution. He is also an entrepreneur who has formed a company called Carmona Robotics. He created an invention, motivated by the work of several thinkers a smartglass with a brain-computer interface that integrates imaging studies, logistics, daily life, and social experiences. Mr. Iavarrones dream is to study biomedical engineering and, specifically, neuronal engineering, and to collaborate with others in improving the effectiveness of biological sensors in prostheses and computational devices. Mr. Iavarrone believes in a world of neurodiversity and existential freedom, where the identity of each person is defended. In addition, he takes an interest in economics and energy and is a member of the Facebook group Transhumanismo, whose focus is on spreading transhumanist ideas in countries throughout the Spanish-speaking world.

Abdul-Rahman Essam Saleh holds a Bachelors degree in Biotechnology and is aiming to establish the biotechnology industry as a major industrial sector in Egypt, where potentials are at a peak and chances seem limitless. For that dream to come true, Abdul is taking steps and planning on doing his Masters degree in Biotechnology Business Management.

Abdul started the Arabian Longevity Alliance initiative to spread awareness of the longevity research field and its results among researchers and science-loving laymen. Also, to spark the interests of people who arent that much into science, Abdul used his stance to start intriguing peoples thoughts about how the Transhumanistic era might look like and how longevity is going to affect the shapes of our lives.

Abdul has held multiple talks, lectures, and YouTube videos on various topics, including longevity, to help get the word out in the Arab world, which is why he pays great regard to translating research papers into Arabic and posting them with the hope that they reach Arabic-speaking audiences interested in the field or in science in general.

Abdul hopes that his efforts result in a possible core of the first small community of Transhumanists in Egypt.

Abdul-Rahman can be contacted via his Facebook pageand his YouTube channel.

Chris Monteiro has been involved in the transhumanist movement for a number of years. He is a co-founder and officer with the Transhumanist Party UK, an organization seeking to tackle a range of contemporary political challenges facing the transhumanist movement in British, European, and international contexts.

Since 2015 he has led the H+Pedia project from Humanity+, a transhumanist edited wiki helping to better map, understand and promote transhumanist ideas within the entire movement.

He works as a systems administrator and studies contemporary cybercrime trends and their intersections with computer security, privacy, and our rapidly developing internet-connected society.

Personal site: https://pirate.london/Twitter: https://twitter.com/Deku_shrub

Chris can be contacted here.

Pam Keefe is the Asia Pacific Vice President for HNI International.

Based in Hong Kong, Pam is responsible for Sales and Distribution of HNIs 8 brands of office furniture, including Allsteel, Gunlocke, Paoli, Lamex, and HNI India. Originally from the USA, she has been working and living in Asia since 2008. Prior to joining HNI in 2015, Pam was based in Singapore and was the Vice-President of Asia Pacific for Teknion Office Furniture for two years and spent 12 years with Haworth Office Furniture, leading Sales Strategy and Global Accounts for Asia Pacific, Middle East, Latin America, and Africa.

In addition to the office furniture business, Pam has a passion for biotechnology, health, fitness, and life extension.

Pam is spearheading an effort to raise awareness and educate people in Asia on the possibilities of life extension and the critical medical research that is needed to cure aging and death. The organizations in which she is involved give her access to people, events, knowledge, and activities that the U.S. Transhumanist Party can leverage. Pam is organizing RAADfest Bangkok, which takes place in February 2018 and will be the first event of its kind in Asia.

Pam can be contacted here.

Palak Madan is a Research Analyst at Blackbox AI. Her work involves evaluating AI marketplace, finding best practices for various operational needs, business development, UI designing, gathering resources for in-house research lab, maintaining internal wiki, etc. Previously, she has participated in diverse challenges and collaborative projects with various tech-startups in India, U.S., and Europe.

Besides AI forecasting, her research work revolves around Future of Machine Intelligence, long-term ethical problems of robust and beneficial Artificial Intelligence, simulation theory, ethical reasoning, rationality, mathematics, and design thinking. She likes to focus on big picture questions facing humanity and maintains a web presence at futuretunnel.com, where she shares her views, thoughts and vision for far future.

Palak can be contacted here.

Dr.Denisa Rensen B.Sc., B.A., N.D. FAARM A4Mis an avid academic/researcher, holding Honors Degrees in Philosophy, in Biology, in Psychology and a Medical Degree in Naturopathic Medicine. She holds a Fellowship in Anti-Aging & Regenerative Medicine from the American Academy of Anti-Aging & Regenerative Medicine A4M.

Denisa is passionate about exponential medicine, conscious transhumanism, and the future of unlimited lifespans. She is a speaker and MC of the RAADFest a yearly conference on ending aging and expanding human lifespans in the most healthy and conscious way possible.

She is a writer, a poet, a photographer,cinematographer, and conscious media producer always bridging art and science in all she does.

Denisa can be contacted here.

Ojochogwu Abdul is a resident of Nigeria and deeply involved in the countrys transhumanist community under the personal philosophies of deep naturalism, transhumanism, and cosmism. Hes the founder of the Transhumanist Enlightenment Caf (TEC) and is the co-founder of the Transhumanist Forum of Nigeria (H+Forum-NG).

Ojochogwu currently holds a B.A. in Philosophy & Religious Studies and an M.A. in Philosophy, and is a Ph.D. student in Philosophy at the University of Lagos, Nigeria. Hes a researcher, philosophy tutor, private consultant, speaker, social worker, and NGO program and planning officer.

Ojochogwu can be contacted here.

Go here to read the rest:
Leadership U.S. Transhumanist Party Official Website

Posted in Transhumanist | Comments Off on Leadership U.S. Transhumanist Party Official Website

Type 2 Diabetes

Posted: November 6, 2018 at 1:45 pm

Start Here! This resource will give you the first steps for managing your type 2 diabetes.

Learn how to test your blood glucose (blood sugar) with the latest tools.

With the correct treatment and recommended lifestyle changes, many people with diabetes are able to prevent or delay the onset of complications.

Get more information about types of medications and how they work.

Work with your doctors to create the best treatment plan for you.

Do you have a new diabetes diagnosis? Need a survival plan? Our step-by-step book of basic diabetes education tells you what to do next!

Treat hypoglycemia (sometimes called an insulin reaction) as soon as possible.

Watch for symptoms of hyperglycemia (high blood glucose) and learn how to treat it.

Bariatric surgery (Gastric Bypass or Laparoscopic Gastric Banding) is sometimes considered for adults with a body mass index (BMI) above 35 and type 2 diabetes.

Recently diagnosed? Let us guide you during your first year with six informational packets to help you learn to live well with diabetes.

This two-page introduction to type 2 diabetes is in PDF format so you can download it, print it, and hand it out to patients.

Continued here:
Type 2 Diabetes

Posted in Diabetes | Comments Off on Type 2 Diabetes

HCG Diet Info – HCG DIET PLAN AUTHORITY – OFFICIAL SITE

Posted: November 6, 2018 at 1:44 pm

This is good news! This means the Hcg weight loss plan can be surprisingly versatile with the right recipes, and can work with any number of menus, foods sensitivities. The allowed foods are clear of processed and prepared foods and carefully measured for portion control. Instead of processed foods, the food list focuses on clean eating, and consists mostly of vegetables and healthy portions of lean protein, along with some, but limited, carbohydrates. To be clear, this is NOT a ketosis diet when done correctly, and in fact the amount of vegetables and fruit permitted, do not allow the body to go into ketosis. Compared to ketosis diets, this particular approach has been shown to average much higher weight loss rates that range from .5 to 1.5 pounds per day.

In a nutshell: TheHcg Diet allowed foodsand guidelines focus on portion control, increased vegetables and proteins, and a food list that is comprised of clean, unprocessed foods.

Learning to cook on the diet, can be a struggle for some patients, however, it is also an excellent opportunity to learn how to cook new foods that are clean, nutritious and healthy. Since the protocol does not allow foods that are processed or prepared (bye bye alcohol, fast food and frozen dinners) this can be an excellent path to learning how to prepare meals that will nourish your body, and make long term weight maintenance easy.

Take a look at our recipe section, and discover amazingHcg Diet Recipes that include Southwestern chicken, strawberry cupcakes, garlic baked shrimp, mouth-watering grilled asparagus, and chai beverages. While it may be intimidating to look at the allowed foods list and feel limited, it wont take long before you realize just how versatile and delishous it can be.

We have also included a list of our best recipe and cooking articles that cover everything from how to cook on the protocol, spices to use to increase your metabolism, tips for dining out and tips for eating during special occasions.

Go here to see the original:
HCG Diet Info - HCG DIET PLAN AUTHORITY - OFFICIAL SITE

Posted in HCG Diet | Comments Off on HCG Diet Info – HCG DIET PLAN AUTHORITY – OFFICIAL SITE

About HCG Diet – HCG Diet

Posted: November 6, 2018 at 1:44 pm

Attention: Individual results may vary from the personal experiences listed on this page. Due to their unique experiences, body types and strictness to the program there are no guarantees for others, who have used or plan to use HCG Triumph, see the same results. Information provided within our site and marketing material is based on historical research, literature and results from the many thousands of former HCG (Human Chorionic Gonaditropin) Triumph clients. The personal experiences listed on this page were submitted for entry to a contest held by HCG Triumph. A before and after photo along with our clients story was required for eligibility to receive a prize. Contact your HCG Triumph weight loss support team now for any questions or concerns. Statements regarding HCG Triumph have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat or cure any disease. FDA STATEMENT: HCG has no known effects on fat mobilization, appetite or sense of hunger, or body fat distribution. HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. There is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or "normal" distribution of fat, or that it decreases the hunger and discomfort associated with calorie restricted diets.

See the rest here:
About HCG Diet - HCG Diet

Posted in HCG Diet | Comments Off on About HCG Diet – HCG Diet

Stem Cell Therapy | Ohio Stem Cell

Posted: November 5, 2018 at 3:44 pm

Amniotic regenerative cell therapy is one of the newest and most cutting-edge therapies for chronic joint pain. Amniotic derived regenerative cell therapy offers patients 3 essential properties for healing and restoring joint health:

Since amniotic derived regenerative cell therapy is not derived from embryonic stem cells or fetal tissue, there are no ethical issues with the treatment. The amniotic regenerative cell therapy consists of an injection directly into the painful area. The therapy has the potential to actually alter the course of the condition and not simply mask the pain. This therapy has significant potential for those in pain, and could actually repair structural problems while treating pain and inflammation simultaneously. When the amniotic cell material is obtained, it comes from consenting donors who have undergone elective c-sections. The fluid is processed at an FDA regulated lab, and is checked for a full slate of diseases per FDA guidelines. The amniotic material has been used over 60,000 times in the US with no adverse events reported. It acts as an immunologically privileged material, meaning it has NOT been shown to cause any rejection reaction in the body. This means there is no graft versus host problem.

Our services are provided by Dr. John Biery D.O. F.A.O.S.M. F.A.C.S.M. F.A.C.O.F.P

Lauren Sherer P.A.

Read more here:
Stem Cell Therapy | Ohio Stem Cell

Posted in Ohio Stem Cells | Comments Off on Stem Cell Therapy | Ohio Stem Cell

Human genetic clustering – Wikipedia

Posted: November 3, 2018 at 6:45 am

Human genetic clustering is the degree to which human genetic variation can be partitioned into a small number of groups or clusters. A leading method of analysis uses mathematical cluster analysis of the degree of similarity of genetic data between individuals and groups in order to infer population structures and assign individuals to hypothesized ancestral groups. A similar analysis can be done using principal components analysis,[1] and several recent studies deploy both methods.[2][3]

Analysis of genetic clustering examines the degree to which regional groups differ genetically, the categorization of individuals into clusters, and what can be learned about human ancestry from this data. There is broad scientific agreement that a relatively small fraction of human genetic variation occurs between populations, continents, or clusters. Researchers of genetic clustering differ, however, on whether genetic variation is principally clinal or whether clusters inferred mathematically are important and scientifically useful.

One of the underlying questions regarding the distribution of human genetic diversity is related to the degree to which genes are shared between the observed clusters. It has been observed repeatedly that the majority of variation observed in the global human population is found within populations. This variation is usually calculated using Sewall Wright's fixation index (FST), which is an estimate of between to within group variation. The degree of human genetic variation is a little different depending upon the gene type studied, but in general it is common to claim that ~85% of genetic variation is found within groups, ~610% between groups within the same continent and ~610% is found between continental groups. Ryan Brown and George Armelagos described this as "a host of studies [that have] concluded that racial classification schemes can account for only a negligible proportion of human genetic diversity," including the studies listed in the table below.

(rather than among populations)

diversity[4]

Cavalli-Sforza

microsatellite loci

These average numbers, however, do not mean that every population harbors an equal amount of diversity. In fact, some human populations contain far more genetic diversity than others, which is consistent with the likely African origin of modern humans.[7][8] Therefore, populations outside of Africa may have undergone serial founder effects that limited their genetic diversity.[7][8]

The FST statistic has come under criticism by A. W. F. Edwards[9] and Jeffrey Long and Rick Kittles.[10] British statistician and evolutionary biologist A. W. F. Edwards faulted Lewontin's methodology for basing his conclusions on simple comparison of genes and rather on a more complex structure of gene frequencies. Long and Kittles' objection is also methodological: according to them the FST is based on a faulty underlying assumptions that all populations contain equally genetic diverse members and that continental groups diverged at the same time. Sarich and Miele have also argued that estimates of genetic difference between individuals of different populations understate differences between groups because they fail to take into account human diploidy.[11]

Keith Hunley, Graciela Cabana, and Jeffrey Long created a revised statistical model to account for unequally divergent population lineages and local populations with differing degrees of diversity. Their 2015 paper applies this model to the Human Genome Diversity Project sample of 1,037 individuals in 52 populations.[8] They found that least diverse population examined, the Surui, "harbors nearly 60% of the total species diversity." Long and Kittles had noted earlier that the Sokoto people of Africa contains virtually all of human genetic diversity.[12] Their analysis also found that non-African populations are a taxonomic subgroup of African populations, that "some African populations are equally related to other African populations and to non-African populations," and that "outside of Africa, regional groupings of populations are nested inside one another, and many of them are not monophyletic."[8]

Multiple studies since 1972 have backed up the claim that, "The average proportion of genetic differences between individuals from different human populations only slightly exceeds that between unrelated individuals from a single population."[13][4][14][5][15][16][17]

Edwards (2003) claims, "It is not true, as Nature claimed, that 'two random individuals from any one group are almost as different as any two random individuals from the entire world'" and Risch et al. (2002) state "Two Caucasians are more similar to each other genetically than a Caucasian and an Asian." However Bamshad et al. (2004) used the data from Rosenberg et al. (2002) to investigate the extent of genetic differences between individuals within continental groups relative to genetic differences between individuals between continental groups. They found that though these individuals could be classified very accurately to continental clusters, there was a significant degree of genetic overlap on the individual level, to the extent that, using 377 loci, individual Europeans were about 38% of the time more genetically similar to East Asians than to other Europeans.

Witherspoon et al. (2007) have argued that even when individuals can be reliably assigned to specific population groups, it may still be possible for two randomly chosen individuals from different populations/clusters to be more similar to each other than to a randomly chosen member of their own cluster, when sampling a small number of SNPs (as in the case with scientists James Watson, Craig Venter and Seong-Jin Kim). They state that using around one-thousand SNPs, individuals from different populations/clusters are never more similar, which they state some may find surprising. Witherspoon et al. conclude that "caution should be used when using geographic or genetic ancestry to make inferences about individual phenotypes".

A 1994 study by Cavalli-Sforza and colleagues evaluated genetic distances among 42 native populations based on 120 blood polymorphisms. The populations were grouped into nine clusters: African (sub-Saharan), Caucasoid (European), Caucasoid (extra-European), northern Mongoloid (excluding Arctic populations), northeast Asian Arctic, southern Mongoloid (mainland and insular Southeast Asia), Pacific islander, New Guinean and Australian, and American (Amerindian). Although the clusters demonstrate varying degrees of homogeneity, the nine-cluster model represents a majority (80 out of 120) of single-trait trees and is useful in demonstrating the phenetic relationship among these populations.[19]

The greatest genetic distance between two continents is between Africa and Oceania, at 0.2470. This measure of genetic distance reflects the isolation of Australia and New Guinea since the end of the Last Glacial Maximum, when Oceania was isolated from mainland Asia due to rising sea levels. The next-largest genetic distance is between Africa and the Americas, at 0.2260. This is expected, since the longest geographic distance by land is between Africa and South America. The shortest genetic distance, 0.0155, is between European and extra-European Caucasoids. Africa is the most genetically divergent continent, with all other groups more related to each other than to sub-Saharan Africans. This is expected, according to the single-origin hypothesis. Europe has a general genetic variation about three times less than that of other continents; the genetic contribution of Asia and Africa to Europe is thought to be two-thirds and one-third, respectively.[19][20]

Genetic structure studies are carried out using statistical computer programs designed to find clusters of genetically similar individuals within a sample of individuals. Studies such as those by Risch and Rosenberg use a computer program called STRUCTURE to find human populations (gene clusters). It is a statistical program that works by placing individuals into one of an arbitrary number of clusters based on their overall genetic similarity, many possible pairs of clusters are tested per individual to generate multiple clusters.[21] The basis for these computations are data describing a large number of single nucleotide polymorphisms (SNPs), genetic insertions and deletions (indels), microsatellite markers (or short tandem repeats, STRs) as they appear in each sampled individual. Cluster analysis divides a dataset into any prespecified number of clusters.

These clusters are based on multiple genetic markers that are often shared between different human populations even over large geographic ranges. The notion of a genetic cluster is that people within the cluster share on average similar allele frequencies to each other than to those in other clusters. (A. W. F. Edwards, 2003 but see also infobox "Multi Locus Allele Clusters") In a test of idealised populations, the computer programme STRUCTURE was found to consistently underestimate the numbers of populations in the data set when high migration rates between populations and slow mutation rates (such as single-nucleotide polymorphisms) were considered.[22] In 2004, Lynn Jorde and Steven Wooding argued that "Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry."[23]

A number of genetic cluster studies have been conducted since 2002, including the following:

In a 2005 paper, Rosenberg and his team acknowledged that findings of a study on human population structure are highly influenced by the way the study is designed.[28][29] They reported that the number of loci, the sample size, the geographic dispersion of the samples and assumptions about allele-frequency correlation all have an effect on the outcome of the study.

In a review of studies of human genome diversity, Guido Barbujani and colleagues note that various cluster studies have identified different numbers of clusters with different boundaries. They write that discordant patterns of genetic variation and high within-population genetic diversity "make[] it difficult, or impossible, to define, once and for good, the main genetic clusters of humankind."[7]

Genetic clustering was also criticized by Penn State anthropologists Kenneth Weiss and Brian Lambert. They asserted that understanding human population structure in terms of discrete genetic clusters misrepresents the path that produced diverse human populations that diverged from shared ancestors in Africa. Ironically, by ignoring the way population history actually works as one process from a common origin rather than as a string of creation events, structure analysis that seems to present variation in Darwinian evolutionary terms is fundamentally non-Darwinian."[30]

A major finding of Rosenberg and colleagues (2002) was that when five clusters were generated by the program (specified as K=5), "clusters corresponded largely to major geographic regions." Specifically, the five clusters corresponded to Africa, Europe plus the Middle East plus Central and South Asia, East Asia, Oceania, and the Americas. The study also confirmed prior analyses by showing that, "Within-population differences among individuals account for 93 to 95% of genetic variation; differences among major groups constitute only 3 to 5%."

Rosenberg and colleagues (2005) have argued, based on cluster analysis, that populations do not always vary continuously and a population's genetic structure is consistent if enough genetic markers (and subjects) are included. "Examination of the relationship between genetic and geographic distance supports a view in which the clusters arise not as an artifact of the sampling scheme, but from small discontinuous jumps in genetic distance for most population pairs on opposite sides of geographic barriers, in comparison with genetic distance for pairs on the same side. Thus, analysis of the 993-locus dataset corroborates our earlier results: if enough markers are used with a sufficiently large worldwide sample, individuals can be partitioned into genetic clusters that match major geographic subdivisions of the globe, with some individuals from intermediate geographic locations having mixed membership in the clusters that correspond to neighboring regions." They also wrote, regarding a model with five clusters corresponding to Africa, Eurasia (Europe, Middle East, and Central/South Asia), East Asia, Oceania, and the Americas: "For population pairs from the same cluster, as geographic distance increases, genetic distance increases in a linear manner, consistent with a clinal population structure. However, for pairs from different clusters, genetic distance is generally larger than that between intracluster pairs that have the same geographic distance. For example, genetic distances for population pairs with one population in Eurasia and the other in East Asia are greater than those for pairs at equivalent geographic distance within Eurasia or within East Asia. Loosely speaking, it is these small discontinuous jumps in genetic distanceacross oceans, the Himalayas, and the Saharathat provide the basis for the ability of STRUCTURE to identify clusters that correspond to geographic regions".[31]

Rosenberg stated that their findings "should not be taken as evidence of our support of any particular concept of biological race (...). Genetic differences among human populations derive mainly from gradations in allele frequencies rather than from distinctive 'diagnostic' genotypes."[24] The study's overall results confirmed that genetic difference within populations is between 93 and 95%. Only 5% of genetic variation is found between groups.[28]

The Rosenberg study has been criticised on several grounds.

The existence of allelic clines and the observation that the bulk of human variation is continuously distributed, has led some scientists to conclude that any categorization schema attempting to partition that variation meaningfully will necessarily create artificial truncations. (Kittles & Weiss 2003). It is for this reason, Reanne Frank argues, that attempts to allocate individuals into ancestry groupings based on genetic information have yielded varying results that are highly dependent on methodological design.[32] Serre and Pbo (2004) make a similar claim:

The absence of strong continental clustering in the human gene pool is of practical importance. It has recently been claimed that "the greatest genetic structure that exists in the human population occurs at the racial level" (Risch et al. 2002). Our results show that this is not the case, and we see no reason to assume that "races" represent any units of relevance for understanding human genetic history.

In a response to Serre and Pbo (2004), Rosenberg et al. (2005) maintain that their clustering analysis is robust. Additionally, they agree with Serre and Pbo that membership of multiple clusters can be interpreted as evidence for clinality (isolation by distance), though they also comment that this may also be due to admixture between neighbouring groups (small island model). Thirdly they comment that evidence of clusterdness is not evidence for any concepts of "biological race".[26]

Clustering does not particularly correspond to continental divisions. Depending on the parameters given to their analytical program, Rosenberg and Pritchard were able to construct between divisions of between 4 and 20 clusters of the genomes studied, although they excluded analysis with more than 6 clusters from their published article. Probability values for various cluster configurations varied widely, with the single most likely configuration coming with 16 clusters although other 16-cluster configurations had low probabilities. Overall, "there is no clear evidence that K=6 was the best estimate" according to geneticist Deborah Bolnick (2008:76-77).[33] The number of genetic clusters used in the study was arbitrarily chosen. Although the original research used different number of clusters, the published study emphasized six genetic clusters. The number of genetic clusters is determined by the user of the computer software conducting the study. Rosenberg later revealed that his team used pre-conceived numbers of genetic clusters from six to twenty "but did not publish those results because Structure [the computer program used] identified multiple ways to divide the sampled individuals". Dorothy Roberts, a law professor, asserts that "there is nothing in the team's findings that suggests that six clusters represent human population structure better than ten, or fifteen, or twenty."[34] When instructed to find two clusters, the program identified two populations anchored around by Africa and by the Americas. In the case of six clusters, the entirety of Kalesh people, an ethnic group living in Northern Pakistan, was added to the previous five.[28][35]

Commenting on Rosenberg's study, law professor Dorothy Roberts wrote that "the study actually showed that there are many ways to slice the expansive range of human genetic variation.

Sarah A. Tishkoff and colleagues analyzed a global sample consisting of 952 individuals from the HGDP-CEPH survey, 2432 Africans from 113 ethnic groups, 98 African Americans, 21 Yemenites, 432 individuals of Indian descent, and 10 Native Australians. A global STRUCTURE analysis of these individuals examined 1327 polymorphic markers, including of 848 STRs, 476 indels, and 3 SNPs. The authors reported cluster results for K=2 to K=14. Within Africa, six ancestral clusters were inferred through Bayesian analysis, which were closely linked with ethnolinguistic heritage. Bantu populations grouped with other Niger-Congo-speaking populations from West Africa. African Americans largely belonged to this Niger-Congo cluster, but also had significant European ancestry. Nilo-Saharan populations formed their own cluster. Chadic populations clustered with the Nilo-Saharan groups, suggesting that most present-day Chadic speakers originally spoke languages from the Nilo-Saharan family and later adopted Afro-Asiatic languages. Nilotic populations from the African Great Lakes largely belonged to this Nilo-Saharan cluster too, but also had some Afro-Asiatic influence due to assimilation of Cushitic groups over the last 3,000 years. Khoisan populations formed their own cluster, which grouped closest with the Pygmy cluster. The Cape Coloured showed assignments from the Khoisan, European and other clusters due to the population's mixed heritage. The Hadza and Sandawe populations formed their own cluster. An Afro-Asiatic cluster was also discerned, with the Afro-Asiatic speakers from North Africa and the Horn of Africa forming a contiguous group. Afro-Asiatic speakers in the Great Lakes region largely belonged to this Afro-Asiatic cluster as well, but also had some Bantu and Nilotic influence due to assimilation of adjacent groups over the last 3,000 years. The remaining inferred ancestral clusters were associated with European, Middle Eastern, Oceanian, Indian, Native American and East Asian populations.[36]

Jinchuan Xing and colleagues used an alternate dataset of human genotypes including HapMap samples and their own samples (296 new individuals from 13 populations), for a total of 40 populations distributed roughly evenly across the Earth's land surface. They found that the alternate sampling reduced the FST estimate of inter-population differences from 0.18 to 0.11, suggesting that the higher number may be an artifact of uneven sampling. They conducted a cluster analysis using the ADMIXTURE program and found that "genetic diversity is distributed in a more clinal pattern when more geographically intermediate populations are sampled."[3]

A study by the HUGO Pan-Asian SNP Consortium in 2009 using the similar principal components analysis found that East Asian and South-East Asian populations clustered together, and suggested a common origin for these populations. At the same time they observed a broad discontinuity between this cluster and South Asia, commenting "most of the Indian populations showed evidence of shared ancestry with European populations". It was noted that "genetic ancestry is strongly correlated with linguistic affiliations as well as geography".[37]

Studies of clustering reopened a debate on the scientific reality of race, or lack thereof. In the late 1990s Harvard evolutionary geneticist Richard Lewontin stated that "no justification can be offered for continuing the biological concept of race. (...) Genetic data shows that no matter how racial groups are defined, two people from the same racial group are about as different from each other as two people from any two different racial groups.[38] This view has been affirmed by numerous authors[14][5][16] and the American Association of Physical Anthropologists since.[10] A.W.F. Edwards as well as Rick Kittles and Jeffrey Long have criticized Lewontin's methodology, with Long noting that there are more similarities between humans and chimpanzees than differences, and more genetic variation within chimps and humans than between them.[10] Edwards also charged that Lewontin made an "unjustified assault on human classification, which he deplored for social reasons".[39] In their 2015 article, Keith Hunley, Graciela Cabana, and Jeffrey Long recalculate the apportionment of human diversity using a more complex model than Lewontin and his successors. They conclude: "In sum, we concur with Lewontins conclusion that Western-based racial classifications have no taxonomic significance, and we hope that this research, which takes into account our current understanding of the structure of human diversity, places his seminal finding on firmer evolutionary footing."[8]

Genetic clustering studies, and particularly the five-cluster result published by Rosenberg's team in 2002, have been interpreted by journalist Nicholas Wade, evolutionary biologist Armand Marie Leroi, and others as demonstrating the biological reality of race.[40][41][42] For Leroi, "Race is merely a shorthand that enables us to speak sensibly, though with no great precision, about genetic rather than cultural or political differences." He states that, "One could sort the world's population into 10, 100, perhaps 1,000 groups", and describes Europeans, Basques, Andaman Islanders, Ibos, and Castillians each as a "race".[42] In response to Leroi's claims, the Social Science Research Council convened a panel of experts to discuss race and genomics online.[43] In their 2002 and 2005 papers, Rosenberg and colleagues disagree that their data implies the biological reality of race.[24][26]

In 2006, Lewontin wrote that any genetic study requires some priori concept of race or ethnicity in order to package human genetic diversity into a defined, limited number of biological groupings. Informed by genetics, zoologists have long discarded the concept of race for dividing groups of non-human animal populations within a species. Defined on varying criteria, in the same species a widely varying number of races could be distinguished. Lewontin notes that genetic testing revealed that "because so many of these races turned out to be based on only one or two genes, two animals born in the same litter could belong to different 'races'".[44]

Studies that seek to find genetic clusters are only as informative as the populations they sample. For example, Risch and Burchard relied on two or three local populations from five continents, which together were supposed to represent the entire human race.[28] Another genetic clustering study used three sub-Saharan population groups to represent Africa; Chinese, Japanese, and Cambodian samples for East Asia; Northern European and Northern Italian samples to represent "Caucasians". Entire regions, subcontinents, and landmasses are left out of many studies. Furthermore, social geographical categories such "East Asia" and "Caucasians" were not defined. "A handful of ethnic groups to symbolize an entire continent mimic a basic tenet of racial thinking: that because races are composed of uniform individuals, anyone can represent the whole group" notes Roberts.[28][45][46]

The model of Big Few fails when including overlooked geographical regions such as India. The 2003 study which examined fifty-eight genetic markers found that Indian populations owe their ancestral lineages to Africa, Central Asia, Europe, and southern China.[47][48] Reardon, from Princeton University, asserts that flawed sampling methods are built into many genetic research projects. The Human Genome Diversity Project (HGDP) relied on samples which were assumed to be geographically separate and isolated.[49] The relatively small sample sizes of indigenous populations for the HGDP do not represent the human species' genetic diversity, nor do they portray migrations and mixing population groups which has been happening since prehistoric times. Geographic areas such as the Balkans, the Middle East, North and East Africa, and Spain are seldom included in genetic studies.[28][50] East and North African indigenous populations, for example, are never selected to represent Africa because they do not fit the profile of "black" Africa. The sampled indigenous populations of the HGDP are assumed to be "pure"; the law professor Roberts claims that "their unusual purity is all the more reason they cannot stand in for all the other populations of the world that marked by intermixture from migration, commerce, and conquest."[28]

King and Motulsky, in a 2002 Science article, state that "While the computer-generated findings from all of these studies offer greater insight into the genetic unity and diversity of the human species, as well as its ancient migratory history, none support dividing the species into discrete, genetically determined racial categories".[51] Cavalli-Sforza asserts that classifying clusters as races would be a "futile exercise" because "every level of clustering would determine a different population and there is no biological reason to prefer a particular one". Bamshad, in 2004 paper published in Nature, asserts that a more accurate study of human genetic variation would use an objective sampling method, which would choose populations randomly and systematically across the world, including those populations which are characterized by historical intermingling, instead of cherry-picking population samples which fit a priori concepts of racial classification. Roberts states that "if research collected DNA samples continuously from region to region throughout the world, they would find it impossible to infer neat boundaries between large geographical groups."[28][52][53][54]

Anthropologists such as C. Loring Brace,[55] philosophers Jonathan Kaplan and Rasmus Winther,[56][56][57][58] and geneticist Joseph Graves,[59] have argued that while it is certainly possible to find biological and genetic variation that corresponds roughly to the groupings normally defined as "continental races", this is true for almost all geographically distinct populations. The cluster structure of the genetic data is therefore dependent on the initial hypotheses of the researcher and the populations sampled. When one samples continental groups the clusters become continental; if one had chosen other sampling patterns the clustering would be different. Weiss and Fullerton have noted that if one sampled only Icelanders, Mayans and Maoris, three distinct clusters would form and all other populations could be described as being clinally composed of admixtures of Maori, Icelandic and Mayan genetic materials.[60] Kaplan and Winther therefore argue that seen in this way both Lewontin and Edwards are right in their arguments. They conclude that while racial groups are characterized by different allele frequencies, this does not mean that racial classification is a natural taxonomy of the human species, because multiple other genetic patterns can be found in human populations that cross-cut racial distinctions. Moreover, the genomic data under-determines whether one wishes to see subdivisions (i.e., splitters) or a continuum (i.e., lumpers). Under Kaplan and Winther's view, racial groupings are objective social constructions (see Mills 1998 [61]) that have conventional biological reality only insofar as the categories are chosen and constructed for pragmatic scientific reasons.

Commercial ancestry testing companies, who use genetic clustering data, have been also heavily criticized. Limitations of genetic clustering are intensified when inferred population structure is applied to individual ancestry. The type of statistical analysis conducted by scientists translates poorly into individual ancestry because they are looking at difference in frequencies, not absolute differences between groups. Commercial genetic genealogy companies are guilty of what Pillar Ossorio calls the "tendency to transform statistical claims into categorical ones".[62] Not just individuals of the same local ethnic group, but two siblings may end up beings as members of different continental groups or "races" depending on the alleles they inherit.[28]

Many commercial companies use data from the International HapMap Project (HapMap)'s initial phrase, where population samples were collected from four ethnic groups in the world: Han Chinese, Japanese, Yoruba Nigerian, and Utah residents of Northern European ancestry. If a person has ancestry from a region where the computer program does not have samples, it will compensate with the closest sample that may have nothing to do with the customer's actual ancestry: "Consider a genetic ancestry testing performed on an individual we will call Joe, whose eight great-grandparents were from southern Europe. The HapMap populations are used as references for testing Joe's genetic ancestry. The HapMap's European samples consist of "northern" Europeans. In regions of Joe's genome that vary between northern and southern Europe (such regions might include the lactase gene), the genetic ancestry test is using the HapMap reference population is likely to incorrectly assign the ancestry of that portion of the genome to a non-European population because that genomic region will appear to be more similar to the HapMap's Yoruba or Han Chinese samples than to Northern European samples.[63] Likewise, a person having Western European and Western African ancestries may have ancestors from Western Europe and West Africa, or instead be assigned to East Africa where various ancestries can be found.[64] "Telling customers that they are a composite of several anthropological groupings reinforces three central myths about race: that there are pure races, that each race contains people who are fundamentally the same and fundamentally different from people in other races, and that races can be biologically demarcated." Many companies base their findings on inadequate and unscientific sampling methods. Researchers have never sampled the world's populations in a systematic and random fashion.[28]

Roberts argues against the use of broad geographical or continental groupings: "molecular geneticists routinely refer to African ancestry as if everyone on the continent is more similar to each other than they are to people of other continents, who may be closer both geographically and genetically.[28] Ethiopians have closer genetic affinity with Armenians than with Bantu populations.[65] Similarly, Somalis are genetically more similar to Gulf Arab populations than to other populations in Africa.[66] Braun and Hammonds (2008) asserts that the misperception of continents as natural population groupings is rooted in the assumption that populations are natural, isolated, and static. Populations came to be seen as "bounded units amenable to scientific sampling, analysis, and classification".[67] Human beings are not naturally organized into definable, genetically cohesive populations.

Software which support genetic clustering calculation.

Go here to read the rest:
Human genetic clustering - Wikipedia

Posted in Human Genetics | Comments Off on Human genetic clustering – Wikipedia

Ohio Stem Cell Treatment Center of Cleveland (Beachwood …

Posted: November 3, 2018 at 6:44 am

Order By RankOrder By PopularityOrder By Posted DateOrder By Title

10 Items Per Page20 Items Per Page40 Items Per Page60 Items Per Page80 Items Per Page100 Items Per Page

Our adipose derived stem cell harvesting and isolation technique yields extremely high numbers of stem cells. In reviewing outcomes data, treatment cell numbers appear to correlate with treatment success. Our cells are actually in a type of soup called Stromal Vascular Fraction SVF which is stem cells bathed in a rich mixture of natural growth factors (Not the same as human growth factor hormone which is only one type of growth factor). Some types of orthopedic and urologic diseases appear to respond better to stem cells that are super enriched with growth factors created by administering Platelet Rich Plasma to the patient. Autologous Platelet Rich Plasma is derived from a patient's own blood drawn at the time of deployment. At CSN we do not add any foreign substances or medications to the stem cells.

Yes. Patients with uncontrolled cancer are excluded. If you have an active infection anywhere in your body you must be treated first. Severely ill patients may require special consideration. Also, anyone with a bleeding disorder or who takes blood thinning medications requires special evaluation before consideration for stem cells.

We know of no documented cases personally or in the literature where serious harm has resulted. All of our patients will be entered into a database to follow and report any adverse reactions. This information is vital to the development of stem cell science. There have been a few reports of serious complications from overseas and these are being thoroughly evaluated by epidemiologists to ascertain the facts. The International Stem Cell Society registry has over 1,000 cases currently registered and only 2% of the treatments were associated with any complications, none of which were considered serious adverse events.

Stem cells can be cryopreserved in the form of liposuction fat for prolonged periods of time. Currently, this service is outsourced to an outside provider known to have excellent quality control. Many patients have been inquiring about banking cells while they are still young since stem cell numbers drop naturally with each decade of life and some advocate obtaining and saving cells to be used later in life as needed.

Different conditions are treated in different ways and there are different degrees of success. If the goal is regeneration of joint cartilage, one may not see expected results until several months after treatment. Some patients may not experience significant improvement and others may see dramatic regeneration of damaged tissue or resolution of disease. Many of the disorders and problems that the physicians at CSN are treating represent pioneering work and there is a lack of data. FDA regulations prevent CSN from making any claims about expectations for success, however, if you are chosen for treatment, it will be explained that we believe stem cell therapy may be beneficial or in some cases that we are unsure and treatment would be considered investigational.

Adult mesenchymal stem cells are not known to cause cancer. Some patients have heard of stories of cancer caused by stem cells, but these are probably related to the use of embryonic cells (Not Adult Mesenchymal Cells). These embryonic tumors known as teratomas are rare but possible occurrences when embryonic cells are used.

No. Many are confused by this because they have heard of cancer patients receiving stem cell transplants. These patients had ablative bone marrow therapy and need stem cells to re-populate their blood and marrow. This is different from the stem cells we deploy to treat noncancerous human diseases at CSN.

No. Only adult mesenchymal stem cells are used. These cells are capable of forming bone, cartilage, fat, muscle, ligaments, blood vessels, and certain organs. Embryonic stem cells are associated with ethical considerations and limitations.

No. Only a person's own adult autologous cells are used. These are harvested from each individual and deployed back into their own body. There is no risk of contamination or risk of introduction of mammalian DNA into the treatments.

Depending on the type of treatment required, stem cells can be injected through veins, arteries, into spinal fluid, subcutaneously, or directly into joints or organs. All of these are considered minimally invasive methods of introducing the stem cells. Stem cells injected intravenously are known to seek out and find (see photo) areas of tissue damage and migrate to that location thus potentially providing regenerative healing. Intravenously injected stem cells have been shown to have the capability of crossing the blood-brain barrier to enter the central nervous system and they can be identified in the patient's body many months after deployment. Note yellow arrow showing the stem cells concentrated in the patient's hand where he had a Dupytren's contracture (Dupuytren's contracture is a hand deformity that causes the tissue beneath the surface of the hand to thicken and contract).

These adult stem cells are known as progenitor cells. This means they remain dormant (do nothing) unless they witness some level of tissue injury. It's the tissue injury that turns them on. So, when a person has a degenerative type problem, the stem cells tend to go to that area of need and stimulate the healing process. We're still not sure if they simply change into the type of injured tissue needed for repair or if they send out signals that induces the repair by some other mechanism. Suffice it to say that there are multiple animal models and a plethora of human evidence that indicates these are significant reparative cells.

Stem cells are harvested under sterile conditions using a special closed system technology so that the cells never come into contact with the environment throughout the entire process from removal to deployment. Sterile technique and antibiotics are also used to prevent infection.

Ohio Stem Cell Treatment Center patients have their fat (usually abdominal) harvested in our special sterile treatment facility under a local anesthetic. The fat removal procedure lasts approximately twenty minutes. Specially designed equipment is used to harvest the fat cells and less than 100cc of fat is required. Post operative discomfort is minimal and there is minimal restriction on activity.

Stem cell therapy relies on the body's own regenerative healing to occur. The regenerative process may take time, particularly with orthopedic patients, who may not see results for several months. In some diseases, more immediate responses are possible.

Most patients, especially those with orthopedic conditions, require only one deployment. Certain types of degenerative conditions, particularly auto-immune disease, may respond best to a series of stem cell deployments. The number and necessity of any additional treatments would be decided on a case by case basis. Financial consideration is given in these instances.

No. Only certain medical problems are currently being treated at CSN. Check our list or fill out a candidate application form on the website. All patients need to be medically stable enough to have the treatment in our facility. There may be some exceptional conditions that may eventually be treated in hospitalized patients, but that remains for the future. Some patients may be declined due to the severity of their problem. Other patients may not have conditions appropriate to treat or may not be covered by our specialists or our protocols. A waiting list or outside referral (if we know of someone else treating such a problem) might be applicable in such cases.

NO. However, the Cell Surgical Network's procedures fall under the category of physician's practice of medicine, wherein the physician and patient are free to consider their chosen course of treatment. The FDA does have guidelines about treatment and manipulation of a patient's own tissues. At CSN we meet these guidelines by providing same day treatment with the patient's own cells that undergo very minimal manipulation and are inserted during the same procedure.

Stem cells are harvested and deployed during the same procedure. Our patients undergo a minimally-invasive liposuction type of harvesting procedure by a Board Certified cosmetic surgeon in our specialized treatment facility in a Treatment Center closest to you. The harvesting procedure generally lasts a few minutes and can be done under local anesthesia. Cells are then processed and are ready for deployment within 90 minutes or less.

CSN is doing pioneer research and treatment of many diseases. All investigational data is being collected so that results will be published in peer review literature and ultimately used to promote the advancement of cellular based regenerative medicine. FDA regulations mandate that no advertising medical claims be made and that even website testimonials are prohibited.

Stem cell therapy is thought to be safe and not affect dormant cancers. If someone has had cancer that was treated and responded sucessfully, there is know reason to withhold stem cell deployment. In most cases, stem cells should not be used in patients with known active cancer.

Results 1 - 20 of 37

More here:
Ohio Stem Cell Treatment Center of Cleveland (Beachwood ...

Posted in Ohio Stem Cells | Comments Off on Ohio Stem Cell Treatment Center of Cleveland (Beachwood …

Adoptive T Cell Therapy 2: Development

Posted: November 2, 2018 at 7:41 am

Cambridge Healthtech Institutes 5th AnnualAugust 30-31, 2018

In 2017, two CAR T cell therapies were approved by the Food and Drug Administration (FDA). With multiple engineered receptors making preclinical impact, many biotech and pharma companies are already entering other clinical trials in a race to get to market. Has this promising field finally reached a tipping point? Technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management remain. Cambridge Healthtech Institutes 5th Annual Adoptive T Cell Therapy 2: Development conference focuses on the steps needed to deliver CAR, TCR, NK, and TIL therapies to the clinic. Overall, this event addresses clinical progress, case studies, and the critical components for making adoptive T cell therapy work.

Final Agenda

Day 1 | Day 2 | Download BrochureSpeaker Biographies | Participating Companies | Emerging Company Showcase Presenters

THURSDAY, August 30

7:45 am Registration & Morning Coffee (Harbor Level)

8:25 Chairpersons Opening Remarks

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

8:30 FEATURED PRESENTATION: A Translational Perspective of Development of Yescarta (Axicabtagene Ciloleucel), a First-in-Class CAR T Cell Product for Diffuse Large B Cell Lymphoma

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

Yescarta (Axicabtagene Ciloleucel) is an anti-CD19 CAR T cell therapy that received approval for treatment of relapsing or refractory DLBCL. This presentation describes key elements of the translational program, correlates of toxicities and durable objective response, product characteristics, patient conditioning, and importance of tumor microenvironment. It also showcases major lessons learned and challenges in developing cell-based immunotherapies.

9:00 NEW: Selected Poster Presentation: TAC-T, A Novel T Cell Therapy, Co-Opts the Endogenous T Cell Receptor for Effective, Safe, and Persistent Tumor Rejection

Christopher W. Helsen, PhD, Director, R&D and Head, Platform Development, Triumvira Immunologics, Inc.

9:30 Predictors of Response to CD19-Specific CAR T Therapy in B-CLL

Jun Xu, PhD, Associate Director, Product Development Laboratory, Center for Advanced Cellular Therapeutics, Perelman Center for Advanced Medicine, University of Pennsylvania

To date, it has not been possible to identify patient- or disease-specific factors that predict why some B-CLL patients and not others have such dramatic responses to CAR T cell treatment. We explored the mechanisms associated with clinical response and lack of response to CAR T therapy, providing evidence for intrinsic T cell fitness in mediating durable anti-tumor responses and long-term complete remissions.

10:00 Coffee Break in the Exhibit Hall (Last Chance for Poster Viewing) (Commonwealth Hall)

10:45 Facing the Challenges of Apheresis Network Management

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

For companies working in cell therapies, managing and maintaining your apheresis (cell collection) network is a critical challenge. How do you know which center is best equipped to handle your needs? How do you evaluate their compliance with FDA and international regulations? Hines discusses the key questions to ask and gives you the tools youll need to evaluate centers, secure your supply chain and advance your cell therapy program.

11:15 Solving the Challenges of Large-Scale GMP T Cell Manufacturing

Steven L. Highfill, PhD, Assistant Director, Product Development and Management, Center for Cellular Engineering, Clinical Center, National Institutes of Health

This presentation covers current, ongoing GMP manufacturing efforts at the NIH. Highlights focus on CAR T cell manufacturing and some of the challenges that we had to overcome specifically when using autologous patient-derived starting material. In addition, I discuss some newer closed-system manufacturing platforms that will make it easier for academic institutes to provide cell therapy options to their patients.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Session Break

1:40 Chairpersons Remarks

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company

1:45 FEATURED PRESENTATION: Stress-Resistant T Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, FACS, FCCP, Associate Attending and Deputy Chief, Thoracic Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan Kettering Cancer Center

CAR T cell therapy efficacy in solid tumors is limited by PD-1/PD-L1 pathway. We have shown that exhausted CAR T cells can be rescued by anti-PD1 agents or by a decoy receptor, PD-1 dominant negative receptor cotransduced with CAR T cells to promote functional persistence. The presentation focuses on cell-intrinsic and extrinsic methods in overcoming checkpoint blockade in cellular immunotherapy.

2:15 TRAP CAR T & Related Cell Therapies: Can Local Delivery Solve Efficacy and Safety Challenges in Solid Tumor Immuno-Oncology?

Janet R. Rea, MSPH, RAC, Senior Vice President, Regulatory, Quality & Clinical Affairs, Atossa Genetics

This presentation reviews cell therapy evolution and challenges. It includes considerations of local delivery options using breast cancer as a model.

2:45 Selected Poster Presentation: Phase I Study of an Adoptive Cellular Immunotherapy by Silencing cbl-b in Autologous Peripheral Blood Mononuclear Cells

Kathrin Thell, PhD, MSc, In Vivo Scientist, Apeiron Biologics AG

3:15 Refreshment Break (Commonwealth Hall)

3:45 Eutilexs 4-1BB CTL Adoptive T Cell Therapy: Clinically Safe and First Efficacy in Solid Tumors

Agustin de la Calle, PhD, CBO, Eutilex Co., Ltd.

Eutilexs 4-1BB CTL therapy is the autologous T cell therapy proven safe in man without treatment-related toxicity and no CRS. Efficacy in hematological cancers and solid tumors: brain, breast, lung, tracheal, pancreatic cancers, CRC and melanoma. Complete remissions were observed in Hodgkins and NK/T cell lymphomas. Phase I safety accepted single dose in terminal patients but relapsed patients became responsive again to further treatments. Leader in COGS: simple outpatient procedure.

4:15 Engineering NK Cells for Enhanced Potency and Persistence

James B. Trager, PhD, Senior Vice President, R&D, Nkarta, Inc.

NK cells form a first line of defense against cancer, and they can be formidable mediators of cytotoxicity and adaptive immunity. Efforts to maximize their potential as cancer therapeutics are hampered by difficulty in expanding NK cells, relatively short in vivo persistence, and the ability of tumor cells to evade NK recognition. We discuss recent progress in overcoming these barriers to successful therapeutic application of NK cells.

4:45 FEATURED PRESENTATION: Tricked-Out CARs: Next-Generation Approaches to Enhance and Optimize CAR T Cell Function

Benjamin Boyerinas, PhD, Senior Scientist, Immunotherapy, bluebird bio

Genetically engineered CAR T cells can be further engineered to survive and overcome immune evasion mechanisms employed by tumors. We have been developing a novel TGF- signal conversion platform that provides a T cell supportive signal upon exposure to TGF- within the hostile tumor microenvironment. This approach, combined with other methodologies such as gene editing and drug-regulated activation, have the potential to enhance specific activity within solid tumors.

5:15 End of Day

Day 1 | Day 2 | Download Brochure

FRIDAY, August 31

7:45 am Registration (Plaza Level)

8:00 Breakout Discussion Groups with Continental Breakfast (Beacon Hill)

This session features discussion groups that are led by a moderator who ensures focused conversations around the key issues listed. Attendees choose to join a specific group, and the small, informal setting facilitates sharing of ideas and active networking. Details on the topics and moderators are available on the conference website.

9:00 Chairpersons Remarks

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

9:05 GOLD: Activation-Induced Payload Delivery for T Cell Therapies

Gus Zeiner, PhD, CSO, Chimera Bioengineering

GOLD is an endogenous post-transcriptional gene regulatory node that couples T cell metabolic states to transgenic payload outputs. Conditional payload expression is induced by signaling through either the native T cell receptor or a CAR. GOLD is payload-agnostic, and enforces low basal payload expression in resting T cells with a wide dynamic range in activated T cells. GOLD-mediated regulation is non-immunogenic, making GOLD-enabled T cell therapeutics compatible with long-term persistence.

9:35 Developing Tumor Infiltrating Lymphocytes for the Treatment of Cancer

Maria Fardis, PhD, President & CEO, Iovance Biotherapeutics

Recent FDA approvals of Kymriah and Yescarta show that cell therapies are viable options for treatment of hematological malignancies. Incidence of solid tumors are, however, approximately 10 times higher than hematological malignancies. Available therapies for solid tumors include chemotherapy, radiotherapy, and immunotherapy. Immunotherapies, such as Anti-PD-1 antibodies, have shown promise, but in many cases, although the overall response rate is not high, discontinuation due to adverse events remains an issue. Iovance is developing -infiltrating lymphocytes (TIL), a one-time cell therapy treatment that leverages and enhances the bodys natural defenses against certain aggressive solid tumors. TIL is currently under investigation in several multi-center Phase II clinical trials and preliminary results have demonstrated safety and efficacy in melanoma, head and neck and cervical cancer patients with multiple prior therapies which constitutes unmet medical need.

10:05 PM21-NK Cells for Cancer Therapy

Robert Igarashi, PhD, President, CytoSen Therapeutics

CytoSen is advancing NK cell therapy for treatment of cancer. CytoSens methods for stimulating NK cells with membrane bound (IL21), originally developed by Dr. Dean A. Lee, produces NK cells with high anti-tumor potency and can generate the highest doses. We plan to leverage our particle-based platform, that has logistical advantages, to pursue clinical studies in leukemia.

10:35 Coffee Break (Plaza Level)

11:00 A TCR-Based Chimeric Antigen Receptor

Even Walseng, PhD, Staff Scientist, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health; Department of Immunology, Hospital Radiumhospitalet, Institute for Cancer Research, University of Oslo

Although CARs are very potent, the recognition is limited to membrane antigens which represent around 1% of the total proteins expressed, whereas TCRs have the advantage of targeting any peptide resulting from cellular protein degradation. To expand the horizon of TCR use, we have successfully fused a soluble TCR construct to a CAR-signaling tail. We demonstrate that the TCR-CAR redirection is not restricted to T cells and hence opens therapeutic avenues combing the killing efficiency of NK cells with the diversified target recognition of TCRs.

11:30 Hijacking CAR19 T Cells to Address Critical Issues in Cell Therapy: Application to Diverse Indications

Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics, Inc.

The Aleta platform addresses critical issues in cell therapy including CAR persistence, antigen escape and antigen heterogeneity, and provides important solutions for treating both hematologic and solid tumors. The key element of our technology is the use of novel fusion proteins to redirect CAR T specificity. Our lead programs are directed to B cell malignancies, AML and solid tumors.

12:00 Close of Adoptive T Cell Therapy 2: Development

Day 1 | Day 2 | Download BrochureSpeaker Biographies | Participating Companies | Emerging Company Showcase Presenters

The rest is here:
Adoptive T Cell Therapy 2: Development

Posted in Cell Therapy | Comments Off on Adoptive T Cell Therapy 2: Development

Page 1,350«..1020..1,3491,3501,3511,352..1,3601,370..»